SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported highlights and financial results for its fourth quarter and fiscal year ended December 31, 2009, and other important recent developments and outlook for 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) Highlights of 2009 and Recent Developments Sale of Cardium's InnerCool Therapies business to Royal Philips Electronics for approximately $11.25 million and transfer of $1.5 million of InnerCool trade payables to Philips;Completion of Tissue Repair Company's Matrix Phase 2b clinical trial of collagen-based products for the potential treatment of non-healing diabetic ulcers;Application for Food and Drug Administration (FDA) 510(k) U.S.

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter ended September 30, 2009, and on recent developments and future outlook.

SAN DIEGO, Aug.

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has entered into a definitive Asset Purchase Agreement for the acquisition of Cardium's InnerCool Therapies business ("InnerCool") by Royal Philips Electronics (NYSE: PHG, AEX: PHI).

SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) and its operating unit InnerCool Therapies today announced the launch of InnerCool's newly redesigned website at www.innercool.com.